FLUVASTATIN (LESKOL) EFFECT ON CLINICAL S TATUS AND HEPATIC-FUNCTION OF PATIENTS WITH ISCHEMIC-HEART-DISEASE

The study included 30 IHD patients with primary hypercholesterolemia ( 22 males and 8 females). 18 and 12 patients have received a single dai ly dose of fluvastatin 20 and 40 mg, respectively, in the evening for 12 weeks. The drug effect was assessed by changes in the clinical stat us, lipid spectrum, transport-metabolic and absorption-secretory funct ions of the liver. IHD patients with hypercholesterolemia were found t o have dysfunction of the hepatobiliary system. Fluvastatin treatment reduced the level of total cholesterol (Ch), LDLP Ch, triglycerides. H DLP Ch levels remained unchanged. Atherogenic lipoproteins aggregation diminished. Positive changes occurred in hepatic metabolism: bilirubi n concentrations lowered, serum albumin went up, absorption-secretory function of hepatocytes normalized, hepatic monooxidase system activat ed. Fluvastatin-related hepatic damage was not reported in tile course of 12-month follow-up.